Precemtabart tocentecan clinical trials
Also written M9140.
How each study uses precemtabart tocentecan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the precemtabart tocentecan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2022 (1)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
EMD Serono Research & Development Institute, Inc. (3) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses precemtabart tocentecan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)RecruitingPhase 3EMD Serono Research & Development Institute, Inc.NCT07549412Written as Precemtabart tocentecan
- Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid TumorsCompletedPhase 1Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT06806046Written as M9140
- Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)Active, not recruitingPhase 1/2EMD Serono Research & Development Institute, Inc.NCT06710132Written as M9140
- Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)Active, not recruitingPhase 1EMD Serono Research & Development Institute, Inc.NCT05464030Written as M9140
Codes
What other systems call precemtabart tocentecan · ClinicalTrials.gg INT018225
- UNII (FDA) V97BV45YBZPRECEMTABART TOCENTECANOne source FDA
- NCI Thesaurus C189819Precemtabart TocentecanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | V97BV45YBZ | PRECEMTABART TOCENTECAN | One source FDA |
| NCI Thesaurus | C189819 | Precemtabart Tocentecan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.